Tolerizing Particles for Celiac Disease Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Celiac disease rely on a strict gluten-free diet, which is difficult to maintain and does not completely prevent intestinal damage, and existing therapies have shown only marginal efficacy in inducing immune tolerance.
Innovation Solution
Administration of tolerizing immune modifying particles (TIMP) encapsulating gliadin antigenic epitopes, which are administered at specific doses and routes to reduce gluten sensitivity and induce immune tolerance, using a polymer matrix of PLGA with a negative zeta potential and targeted antigen presentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a strict gluten-free diet is implemented, then symptoms of Celiac disease are alleviated, but complete elimination of gluten is difficult to maintain and intestinal damage is not completely prevented
Solution Approach 1:
The patent uses tolerizing immune modifying particles as an intermediary substance that delivers gliadin antigen epitopes to the immune system in a controlled manner. These particles act as a mediator between the harmful gluten protein and the immune system, inducing tolerance without requiring complete gluten elimination from the diet.
Solution Approach 2:
The treatment applies preliminary immune modulation before gluten exposure occurs. By pre-treating patients with tolerizing particles that contain gliadin epitopes, the immune system is prepared to tolerate gluten exposure, preventing intestinal damage before it occurs rather than relying on post-exposure dietary management.
2Reliability
If existing immune tolerance therapies are administered, then immune tolerance is attempted to be induced, but only marginal efficacy is achieved in clinical trials
Solution Approach 1:
The patent changes key parameters of immune tolerance therapy by using specifically engineered particles with controlled physical and chemical properties. The particles have optimized size (100-1000 nm), surface charge (negative zeta potential), and antigen loading capacity, which together improve uptake by antigen-presenting cells and enhance therapeutic efficacy compared to previous approaches.
Solution Approach 2:
The tolerizing immune modifying particles are composite structures combining biodegradable polymer materials (PLGA or chitosan) with gliadin antigen epitopes. This composite approach allows the antigen to be delivered in a protected, stable form that enhances immunogenicity and tolerization effectiveness while the polymer matrix provides controlled release and improved biodistribution.
3Reliability
If tolerizing immune modifying particles are administered, then gluten sensitivity is reduced and immune tolerance is induced, but the complexity of particle formulation and administration increases
Solution Approach 1:
The patent applies local quality by concentrating the therapeutic effect at the specific site of action - the particles are designed to be selectively taken up by antigen-presenting cells in lymphoid tissues. The gliadin epitopes are embedded within the particle matrix at specific locations that optimize presentation to immune cells, while the rest of the particle structure provides protective and delivery functions.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to methods for treating Celiac Disease using tolerizing immune modifying particles that encapsulate antigenic material from the gliadin protein or other related proteins.